Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ghenadie MordvinovfiledCriticalGhenadie Mordvinov
Priority to MD98-0206ApriorityCriticalpatent/MD1226G2/en
Publication of MD1226F1publicationCriticalpatent/MD1226F1/en
Publication of MD1226G2publicationCriticalpatent/MD1226G2/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicinal Preparation
(AREA)
Abstract
The invention relates to the medicine and is provided for treatment of patients having rheumatoid diseases. The proposed preparation comprises the thermally modified human G immunoglobulin in the form of a 10% aqueous solution and a corpuscular carrier in the form of a 10- 16% aqueous suspension of sterile conserved human erythrocytes in the volume ratio of components respectively within the li-mits of 1:6...1:10. The technical result consists in the inhibition of the rheumatoid factor synthesis, in the immunostimulating and anti-inflammatory action and in the creation of a deposition effect. Claims: 3
MD98-0206A1998-10-061998-10-06Preparation for treatment of rheumatoid diseases
MD1226G2
(en)
Use of 9-deoxy-2',9-methano-3-oxa-4,5,6-trinor-3,7-(1',3'interphenylene)-13,14-dihydroprostaglandin F1 to treat peripheral vascular disease
Process for the production of hydroximethyl-(methylene-cyclopentyl)-purines and pirimidines, their medically usable salts, and of medical preparations containing them